Taken together, our findings reveal that OPN contributes to acquired EGFR-TKI resistance by up-regulating expression of integrin αVβ3, which activates the downstream FAK/AKT and ERK signalling pathways to promote cell proliferation in NSCLC (Fig. 7i). The gene discussed is AKT1; the disease is non-small cell lung carcinoma.